Last reviewed · How we verify
Tachosil fibrin patch
TachSil is a fibrin-coated collagen patch that promotes hemostasis by providing a scaffold for clot formation and delivering fibrinogen and thrombin to the wound site.
TachSil is a fibrin-coated collagen patch that promotes hemostasis by providing a scaffold for clot formation and delivering fibrinogen and thrombin to the wound site. Used for Hemostasis support in surgical bleeding during general, cardiac, and vascular surgery, Bleeding control in liver resection and other parenchymal organ surgery.
At a glance
| Generic name | Tachosil fibrin patch |
|---|---|
| Also known as | EU registration number: EU/1/04/277/002 |
| Sponsor | Ruhr University of Bochum |
| Drug class | Hemostatic agent; topical fibrin sealant patch |
| Target | Fibrinogen; Factor II (thrombin) |
| Modality | Small molecule |
| Therapeutic area | Surgery; Hemostasis |
| Phase | Phase 3 |
Mechanism of action
The patch consists of a collagen fleece coated with fibrinogen and thrombin. When applied to a bleeding surface, the thrombin activates the fibrinogen to form fibrin, which polymerizes and creates a stable clot. The collagen substrate provides structural support and enhances platelet adhesion and aggregation, accelerating hemostasis at the site of application.
Approved indications
- Hemostasis support in surgical bleeding during general, cardiac, and vascular surgery
- Bleeding control in liver resection and other parenchymal organ surgery
Common side effects
- Infection at application site
- Seroma formation
- Allergic reaction
Key clinical trials
- GATT-Patch Versus TachoSil in Liver Surgery (NA)
- A Study Evaluating the Safety and Preliminary Efficacy of sFilm-FS in Controlling Parenchymal Bleeding During Elective Hepatic Surgery (PHASE1, PHASE2)
- Use of Fibrin Sealant Patch for Vein Anastomosis During Deceased Donor Liver Transplantation- Randomized Clinical Trial (PHASE4)
- Neoveil® Versus TachoSil® for the Treatment of Pulmonary Air Leaks Following Lung Operation (NA)
- Tachosil for the Prevention of Symptomatic Lymph Cysts (PHASE3)
- The Effect of Application of TachoSil® in Pancreatoduodenectomy (PHASE4)
- Comparison of Efficacy and Safety of TachoSil® Versus Surgicel® Original for the Secondary Hemostatic Treatment of Needle Hole Bleeding in Vascular Surgery (PHASE3)
- Comparison of the Hemostatic Patch to Fibrin Sealant (TachoSil®) in Subjects Undergoing Hepatic Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tachosil fibrin patch CI brief — competitive landscape report
- Tachosil fibrin patch updates RSS · CI watch RSS
- Ruhr University of Bochum portfolio CI